The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered Parkinson’s candidate over the finish line. Milton Werner, Ph.D., is the ...

BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical ...

Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ...

(MENAFN- GlobeNewsWire - Nasdaq) Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase ...

BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small ...

Inhibikase Therapeutics Stock Down 4.8% Shares of Inhibikase Therapeutics stock opened at $2.00 on Monday. The firm has a market cap of $148.68 million, a PE ratio of -0.75 and a beta of 1.01.

Detailed price information for Inhibikase Therapeutics Inc (IKT-Q) from The Globe and Mail including charting and trades.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT ...